Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$17.49 USD

17.49
889,531

+0.06 (0.34%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $17.48 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alcon (ALC) on Track With Successful Global PRECISION1 Rollout

by Zacks Equity Research

Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.

Zacks Equity Research

Veeva's (VEEV) Data Cloud to Aid PharmaEssentia's New Product

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Commercial Cloud business.

Zacks Equity Research

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).

Zacks Equity Research

Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Veeva Systems (VEEV) owing to its strong product portfolio.

Zacks Equity Research

Study Favors Masimo's (MASI) SedLine for Better Patient Outcome

by Zacks Equity Research

Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.

Zacks Equity Research

CVS Health (CVS) Scales a 52-Week High: What's Driving It?

by Zacks Equity Research

Robust performance by the Pharmacy Services and Health Care Benefits arms is driving the top line for CVS Health (CVS).

Zacks Equity Research

Hologic (HOLX) Reports New Findings on Breast Cancer Index

by Zacks Equity Research

Hologic's (HOLX) latest data on Breast Cancer Index demonstrates its effectiveness in predicting net benefit from extended endocrine therapy.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

PerkinElmer's (PKI) Latest Kit to Boost COVID-19 Surveillance

by Zacks Equity Research

PerkinElmer's (PKI) newest addition to its SARS-CoV-2 testing portfolio is expected to aid in combating the pandemic by boosting surveillance.

Zacks Equity Research

Here's Why You Should Hold on to Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.

Zacks Equity Research

Thermo Fisher (TMO) Completes Acquisition of Leading CRO

by Zacks Equity Research

Thermo Fisher's (TMO) acquisition of PPD is likely to bolster its Laboratory Products and Services arm.

Zacks Equity Research

Here's Why Investors Should Hold Onto Ensign Group (ENSG)

by Zacks Equity Research

Riding high on a solid portfolio and a rising top line, Ensign Group (ENSG) holds enough potential to reap benefits for investors.

Zacks Equity Research

BD's (BDX) Tissuemed Buyout to Boost its Surgical Solutions Arm

by Zacks Equity Research

BD's (BDX) latest acquisition is expected to complement its currently used products and help to support minimally invasive surgeries.

Zacks Equity Research

PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research

by Zacks Equity Research

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.

Zacks Equity Research

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.

Zacks Equity Research

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Zacks Equity Research

HealthEquity (HQY) Q3 Earnings Beat, FY 2022 View Lowered

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust Interchange revenues in the third quarter of fiscal 2022.

Zacks Equity Research

Here's Why You Should Retain Abiomed (ABMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.

Zacks Equity Research

BD's (BDX) Buyout of Venclose to Improve Patient Outcome

by Zacks Equity Research

BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.

Zacks Equity Research

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

Zacks Equity Research

Cooper Companies (COO) Q4 Earnings Lag Estimates, Margins Up

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results reflect solid segmental and geographical performances.

Zacks Equity Research

Has AMN Healthcare Services (AMN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AMN Healthcare Services (AMN) and Apollo Endosurgery, Inc. (APEN) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.

Zacks Equity Research

Veeva Systems (VEEV) Q3 Earnings Beat Estimates, '22 View Up

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both its segments.

Zacks Equity Research

Can AMN Healthcare (AMN) Stock Continue to Grow Earnings?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider AMN Healthcare (AMN).